Whole-Person Oncology: Making Multidisciplinary Care and Access the Standard

Executive summary

Ebonie Michelle and Barry Nelson described a pattern biopharma teams see downstream in evidence, trials, and adoption: the science can be ready, but the care model often is not. Their outcomes improved when care became coordinated, multidisciplinary, and built around the whole person. Their risk increased when care was fragmented, dismissive, or narrowly focused on the tumor.

For biopharma and biotech leaders, whole-person oncology should be a delivery requirement. It determines whether a medicine’s value story can be executed across real sites, real lives, and real constraints.

Why this matters now

Oncology care increasingly depends on multiple, connected decisions being made in the right order. In the session, Angela explicitly framed this as “innovation in precision diagnostics,” including imaging agents, genomics, and genetic testing, and asked how those tools change the patient journey.  Ebonie’s story then makes the point concrete: a different MRI capability at a second institution helped identify disease that a standard workup might have missed.

Even when advanced diagnostics and treatment options exist, patients still have to navigate a system with multiple specialties, uneven coordination, and uneven access to comprehensive centers.

This matters to biopharma because inconsistency in care is not contained to the clinic where it starts. It changes what patients are eligible for, what treatment they actually receive, and what outcomes get attributed to the therapy versus the pathway.

It can show up as:

• Lost trial eligibility because the order and timing of treatment steps are inconsistent, including the reality Ebonie flagged directly that once treatment starts, clinical trials are often off the table
• Discontinuation driven by unmanaged burden, meaning side effects, functional decline, or logistics and support gaps that make it hard to stay on therapy even when the drug may be working
• Real-world outcomes that are harder to interpret and defend because supportive care, monitoring, and follow-up vary by site
• Access friction when payers question whether delivery is scalable outside major centers

Ebonie summarized the impact of multidisciplinary care in practical terms: it “provides knowledge, it provides clarity, but it also provides options.” In this context, “options” are specific and operational: access to the right specialists (not only oncology), timely second opinions, consideration of clinical trials before eligibility is closed off, supportive care like PT/OT, and mechanisms like virtual tumor boards that can bring expertise to patients who cannot travel.

Three benefits that multidisciplinary care delivered in practice

1. When the care team is coordinated, the patient is not left to coordinate care on their own

Barry described receiving inconsistent guidance about prognosis across teams during chemotherapy and radiation, and having to push to get everyone in the same room. When the teams were not aligned, confusion, delays, and uncertainty arose. The patient was left trying to reconcile conflicting messages while also making high-stakes decisions.

Takeaway: If your therapy requires steps to happen in a particular order, ongoing monitoring, dose changes, or a timely switch to another option, team alignment is part of the evidence-to-outcomes chain. Assuming coordination will “sort itself out” site by site can cause results to vary in the real world.

2. Ongoing supportive care is important even when treatment are successful

Ebonie highlighted the need for sexual health and wellness support as a core part of whole-person care. For someone with breast cancer, supportive care needs to be more than a single conversation about breast reconstruction or sexual activity. Barry described persistent functional limitations even after treatment conclusion, including shortness of breath that changed his ability to swim. Together, their stories point to the same issue: cancer progress needs to move beyond tumor shrinkage or eradication and include improved safety and quality of life during treatment and after it.

Takeaway: Real-world value is judged by persistence, function, and recoverability, not only response rates. If the value story measures response and survival but does not account for lived burden and longer-term function, the value proof becomes harder to defend with clinicians, payers, and health systems after launch.

3. Whole-person care reduces the mental burden that cancer creates

Ebonie described a common experience many patients carry inside themselves: “there’s always two beasts… there is that one that is going to go hard and fight… but there is that other side that is fearful… withdrawn… lost.” Both Ebonie and Barry pushed through fear and loss, confronting doctors and changing care teams in search of a team that would better support their goals. Upon receiving a cancer diagnosis, patients should not have to educate themselves, fight harder for quality care, and coordinate their own healthcare team. Ebonie describes progress as a care model inclusive of a multidisciplinary team that provides patients with clarity, skills and a complete toolkit to reduce the mental burden while preparing for the physical battle.

Takeaway: If supportive care depends on confidence, education, or confrontation, the pathway will under-serve the patients at highest risk of dropping off. That shows up as discontinuation, poorer outcomes, and evidence that is less representative of who the product is meant to help.

Scaling whole-person care beyond major centers

The session reinforced a hard truth: multidisciplinary care often becomes real only after a patient reaches the right cancer center with the right operating model. Ebonie and Barry both described having to change institutions to get the care approach they needed. The third panelist, who could not attend due to recurrence and impending chemo-radiation, emphasized that remote or virtual tumor boards can be critical for patients in rural areas for those who cannot travel. Ebonie added a concrete example of geography, describing her grandmother living in a small town where the oncologist was more than 45 miles away.

For biopharma, the implication is direct. Real-world performance will be shaped by where patients start care and what capabilities that center can deliver, not only by biology. That effect is amplified when advanced diagnostics, clinical trial awareness, supportive care, and survivorship follow-up are unevenly available.

This is where remote / virtual care platforms can matter, but only if they extend expertise without weakening accountability. Virtual tumor boards and collaboration workflows can bring multidisciplinary input closer to where patients live, but they require governance that makes decisions auditable and responsibilities clear:

• Ownership is explicit, including who updates pathways and adjudicates exceptions
• Outputs are traceable, including what guidance was delivered and when
• Human accountability is clear, including who makes final decisions and how patient preference is captured

Considerations for biopharma

You cannot rebuild oncology delivery. You can design your program so whole-person care is more likely to happen where your asset is used.

Patients want a multidisciplinary care model

• Enable sites with simple coordination expectations that fit routine care, including defined handoffs, shared decision points, and escalation triggers for misalignment
• Provide site-facing tools that standardize how key choices are discussed, including sequencing constraints, monitoring cadence, and when to revisit the plan

Multidisciplinary input must be available without relocation

• Partner with centers and networks to operationalize virtual tumor boards and remote specialist input, with clear decision ownership and documented recommendations
• Invest in workflow integration that reduces missed handoffs, rather than adding standalone tools that create new friction

 Supportive care needs to start early, not after deterioration

• Build supportive care expectations into protocols, evidence plans, and site enablement, including symptom management pathways and functional follow-up
• Treat survivorship and late effects as part of the value story, so post-treatment function is measured and acted on

Trial consideration must happen early enough to matter

• Design trial education and workflows so eligibility is evaluated before standard treatment forecloses participation, aligned with the reality Ebonie highlighted about how quickly trials can come off the table once therapy starts
• Equip sites with referral pathways and patient-facing explanations that reduce the burden of “asking the right question at the right time”

The takeaway for biopharma

Ebonie and Barry described what changed their trajectories: not only better tools, but a care model that could use those tools while still treating them as whole people. When multidisciplinary care reduced care coordination and navigation burden, the clinical advances became usable in real life. Their stories also exposed the scalability constraint: too much of that holistic care model remains concentrated in a limited number of urban centers.

The opportunity is to operationalize whole-person oncology care as a program design requirement. When coordination, access, and survivorship are treated as part of the value story, outcomes improve and value proof holds up under scrutiny.